(1995). Altered relation between circulating levels of insulin-like growth factorbinding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects.
(2003). Assay for cross-linked carboxyterminal telopeptide of type I collagen (ICTP) unlike CrossLaps assay reflects increased pathological degradation of type I collagen in rheumatoid arthritis. Clin Chem Lab Med
(1992). Avioli L: Effects of deflazacort on aspects of bone formation in cultures of intact calvariae and osteoblastenriched cells.
(1996). Bijlsma JW: Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis
(1984). BL: Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum
(1985). C: The effect of glucocorticoids on bone mass in rheumatoid arthritis patients. Influence of menopausal state. Arthritis Rheum
(1991). CA: Bone mineral content in patients with rheumatoid arthritis: relationship to lowdose steroid therapy.
(1994). Canalis E: Cellular and clinical perspectives on skeletal insulin-like growth factor I.
(2005). CJ: Serum insulin-like growth factor binding protein-1 levels and bone mineral density in older adults: the Rancho Bernardo Study. Osteoporos Int
(1991). Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGFII radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh)
(2002). Does active treatment of rheumatoid arthritis limit disease-associated bone loss? Rheumatology (Oxford)
(1996). Endert E: The effect of long-term prednisone treatment on growth hormone and insulin-like growth factor-1.
(1994). Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis
(2003). Foged NT, Delaisse JM: The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res
(2006). Giustina A: Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab
(2001). Guidelines on the use of biochemical markers of bone turnover in osteoporosis
(2005). Hafstrom I: Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum
(2007). Hafstrom I: Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density.
(1994). Increased type I collagen degradation in early rheumatoid arthritis.
(1993). Insulin-like growth factor (IGF) I and II and IGF binding protein
(2003). Insulin-like growth factors (IGFs) and IGF-binding proteins in nephrotic syndrome children on glucocorticoid. Pharmacol Res
(1993). JA: Risk of vertebral fracture in women with rheumatoid arthritis. BMJ
(2001). KO: IGFs and IGF-binding proteins in short children with steroid-dependent nephrotic syndrome on chronic glucocorticoids: changes with 1 year exogenous GH.
(2008). KW: Regulation of IGF-I function by proinflammatory cytokines: At the interface of immunology and endocrinology. Cell Immunol
(1993). Lemmens JA: Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med
(2003). Lems WF: Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. Arthritis Rheum
(1997). Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases.
(2003). LS: Low dose glucocorticoids in early rheumatoid arthritis. Clin Exp Rheumatol